Literature DB >> 16392815

Design and synthesis of photoaffinity-labeling ligands of the L-prolyl-L-leucylglycinamide binding site involved in the allosteric modulation of the dopamine receptor.

Abigail Fisher1, Amandeep Mann, Vaneeta Verma, Nancy Thomas, Ram K Mishra, Rodney L Johnson.   

Abstract

Pro-Leu-Gly-NH(2) (PLG), in addition to its endocrine effects, possesses the ability to modulate dopamine D(2) receptors within the central nervous system. However, the precise binding site of PLG is unknown. Potential photoaffinity-labeling ligands of the PLG binding site were designed as tools to be used in the identification of the macromolecule that possesses this binding site. Six different photoaffinity-labeling ligands were designed and synthesized on the basis of the gamma-lactam PLG peptidomimetic 1. The 4-azidobenzoyl and 4-azido-2-hydroxybenzoyl photoaffinity-labeling moieties were placed at opposite ends of PLG peptidomimetic 1 to generate a series of ligands that potentially could be used to map the PLG binding site. All of the compounds that were synthesized possessed activity comparable to or better than PLG in enhancing [(3)H]-N-propylnorapomorphine agonist binding to dopamine receptors. Photoaffinity ligands that were cross-linked to the receptor preparation produced a modulatory effect that was either comparable to or greater than the increase in agonist binding produced by the respective ligands that were not cross-linked to the dopamine receptor. The results indicate that these photoaffinity-labeling agents are binding at the same allosteric site as PLG and PLG peptidomimetic 1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16392815      PMCID: PMC2533518          DOI: 10.1021/jm050644n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  18 in total

1.  Modulation of agonist stimulated adenylyl cyclase and GTPase activity by L-pro-L-leu-glycinamide and its peptidomimetic analogue in rat striatal membranes.

Authors:  R K Mishra; M H Makman; W J Costain; V D Nair; R L Johnson
Journal:  Neurosci Lett       Date:  1999-07-02       Impact factor: 3.046

2.  Beta-analogs of PLG (L-prolyl-L-leucyl-glycinamide): ex-chiral pool syntheses and dopamine D2 receptor modulating effects.

Authors:  C Thomas; U Ohnmacht; M Niger; P Gmeiner
Journal:  Bioorg Med Chem Lett       Date:  1998-10-20       Impact factor: 2.823

3.  Photoaffinity labeling.

Authors:  H Bayley; J R Knowles
Journal:  Methods Enzymol       Date:  1977       Impact factor: 1.600

4.  Potentiation of apomorphine action in rats by l-prolyl-l-leucyl-glycine amide.

Authors:  R M Kostrzewa; A J Kastin; S K Sobrian
Journal:  Pharmacol Biochem Behav       Date:  1978-09       Impact factor: 3.533

5.  Pro-Leu-glycinamide and its peptidomimetic, PAOPA, attenuate haloperidol induced vacuous chewing movements in rat: A model of human tardive dyskinesia.

Authors:  S Sharma; P Paladino; J Gabriele; H Saeedi; P Henry; M Chang; R K Mishra; R L Johnson
Journal:  Peptides       Date:  2003-02       Impact factor: 3.750

6.  Modulation of agonist binding to human dopamine receptor subtypes by L-prolyl-L-leucyl-glycinamide and a peptidomimetic analog.

Authors:  Vaneeta Verma; Amandeep Mann; Willard Costain; Giuseppe Pontoriero; Jessica M Castellano; Kevin Skoblenick; Suresh K Gupta; Zdenek Pristupa; Hyman B Niznik; Rodney L Johnson; Venugopalan D Nair; Ram K Mishra
Journal:  J Pharmacol Exp Ther       Date:  2005-08-26       Impact factor: 4.030

7.  Synthesis and dopamine receptor modulating activity of 3-substituted gamma-lactam peptidomimetics of L-prolyl-L-leucyl-glycinamide.

Authors:  Kristine Dolbeare; Giuseppe F Pontoriero; Suresh K Gupta; Ram K Mishra; Rodney L Johnson
Journal:  J Med Chem       Date:  2003-02-27       Impact factor: 7.446

8.  L-prolyl-l-leucyl-glycinamide and its peptidomimetic analog 3(R)-[(2(S)-pyrrolidylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) attenuate haloperidol-induced c-fos expression in the striatum.

Authors:  M C Ott; W J Costain; R K Mishra; R L Johnson
Journal:  Peptides       Date:  2000-02       Impact factor: 3.750

9.  Binding studies of L-prolyl-L-leucyl-glycinamide (PLG), a novel antiparkinsonian agent, in normal human brain.

Authors:  S Chiu; Y W Wong; J A Ferris; R L Johnson; R K Mishra
Journal:  Pharmacol Res Commun       Date:  1983-01

10.  Iso-lactam and reduced amide analogues of the peptidomimetic dopamine receptor modulator 3(R)-[(2(S)-pyrrolidinylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide.

Authors:  Kristine Dolbeare; Giuseppe F Pontoriero; Suresh K Gupta; Ram K Mishra; Rodney L Johnson
Journal:  Bioorg Med Chem       Date:  2003-09-01       Impact factor: 3.641

View more
  11 in total

Review 1.  Concepts for biologically active peptides.

Authors:  Abba J Kastin; Weihong Pan
Journal:  Curr Pharm Des       Date:  2010-10       Impact factor: 3.116

2.  Allosteric modulation of the dopamine D2 receptor by Pro-Leu-Gly-NH2 peptidomimetics constrained in either a polyproline II helix or a type II beta-turn conformation.

Authors:  Bhooma Raghavan; Kevin J Skoblenick; Swapna Bhagwanth; Niran Argintaru; Ram K Mishra; Rodney L Johnson
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

3.  Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors.

Authors:  J Robert Lane; Pavel Chubukov; Wei Liu; Meritxell Canals; Vadim Cherezov; Ruben Abagyan; Raymond C Stevens; Vsevolod Katritch
Journal:  Mol Pharmacol       Date:  2013-09-10       Impact factor: 4.436

4.  Evaluation of Density Functionals, SCC-DFTB, Neglect of Diatomic Differential Overlap (NDDO) Models and Molecular Mechanics Methods for Prolyl-Leucyl-Glycinamide (PLG) and Structural Derivatives.

Authors:  Richard L Wood; Brendan J Young-Dixon; Abhrajeet Roy; Bryant C Gay; Rodney L Johnson; Elizabeth A Amin
Journal:  Theochem       Date:  2010-03-30

5.  Specific binding of photoaffinity-labeling peptidomimetics of Pro-Leu-Gly-NH2 to the dopamine D2L receptor: evidence for the allosteric modulation of the dopamine receptor.

Authors:  Amandeep Mann; Vaneeta Verma; Dipannita Basu; Kevin J Skoblenick; Michael G R Beyaert; Abigail Fisher; Nancy Thomas; Rodney L Johnson; Ram K Mishra
Journal:  Eur J Pharmacol       Date:  2010-05-27       Impact factor: 4.432

6.  Transformation of Pro-Leu-Gly-NH2 peptidomimetic positive allosteric modulators of the dopamine D2 receptor into negative modulators.

Authors:  Swapna Bhagwanth; Satyendra Mishra; Ritesh Daya; Jordan Mah; Ram K Mishra; Rodney L Johnson
Journal:  ACS Chem Neurosci       Date:  2012-01-13       Impact factor: 4.418

Review 7.  Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts.

Authors:  Eric A Wold; Jianping Chen; Kathryn A Cunningham; Jia Zhou
Journal:  J Med Chem       Date:  2018-08-28       Impact factor: 7.446

8.  Synthesis and biological evaluation of indole-2-carboxamides bearing photoactivatable functionalities as novel allosteric modulators for the cannabinoid CB1 receptor.

Authors:  Chang-Jiang Qiao; Hamed I Ali; Kwang H Ahn; Srikanth Kolluru; Debra A Kendall; Dai Lu
Journal:  Eur J Med Chem       Date:  2016-05-24       Impact factor: 6.514

9.  Allosteric modulation of the dopamine receptor by conformationally constrained type VI beta-turn peptidomimetics of Pro-Leu-Gly-NH2.

Authors:  Ashish P Vartak; Kevin Skoblenick; Nancy Thomas; Ram K Mishra; Rodney L Johnson
Journal:  J Med Chem       Date:  2007-12-01       Impact factor: 7.446

10.  Development of peptidomimetic ligands of Pro-Leu-Gly-NH(2) as allosteric modulators of the dopamine D(2) receptor.

Authors:  Swapna Bhagwanth; Ram K Mishra; Rodney L Johnson
Journal:  Beilstein J Org Chem       Date:  2013-01-30       Impact factor: 2.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.